BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  A Fundamentally Different View into Complex Neurological Diseases

  Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.

  September 29, 2021

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Gene Editing Breakthroughs Accelerate Heart, Stroke Research

  Gene therapy research delivers breakthroughs this week with a CRISPR-edited droplet that could lead to a cure for heart disease and the possibility of turning glial brain cells into neurons.

  September 29, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  BioMidwest

  Horizon Therapeutics Touts Five New Development Programs on R&D Day

  Horizon was adding five new development programs for daxdilimab and dazodalibep. This brings the company’s pipeline to 27 development programs.

  September 29, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Editas Sees Light in First Data from In Vivo CRISPR Eye Therapy

  EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.

  September 29, 2021

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Policy

  CRO Data Integrity Concerns Have Pharma Companies Scrambling to Repeat Bioequivalence Studies

  The announcement came following independent FDA analyses of inspections conducted at the two CROs in November 2019.

  September 29, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  BioMidwest

  Money on the Move: September 22 – 28

  These life sciences companies are falling into some cold, hard investment cash.

  September 29, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Drug Development

  New Relief for Migraine Sufferers as FDA Approves AbbVie’s Atogepant

  Qulipta is the first calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for this indication.

  September 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  China’s I-Mab Said to be Seeking Biopharma Partnerships, Possible Equity Sale

  The news sparked a mini-surge in shares of I-Mab, which were up 7.8% in pre-market U.S trading on September 28.

  September 29, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Global Roundup: Partnership Aims to Bolster Drug Discovery in Africa

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  September 29, 2021

   · 

  9 min read

   · 

  Alex Keown
• 

  Deals

  Report: Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

  Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.

  September 29, 2021

   · 

  2 min read

   · 

  Alex Keown